Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 13,749 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Adenoid Cystic Carcinoma
Interventions: 177Lu-PNT2002; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions: Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss; Drug · Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tourette Syndrome
Interventions: Medtronic Activa Deep Brain Stimulation System; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 15 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opiate Dependence
Interventions: Patient-Centered Methadone Treatment, Methadone Treatment as usual; Other
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Nosocomial Infections
Interventions: 2% Chlorhexidine gluconate cloth; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 2 Months to 25 Years
Enrollment: 5,659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Pelvic Organ Prolapse, Urinary Incontinence, Patient Education
Interventions: Educational Intervention with video; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Huntington Disease
Interventions: SAGE-718, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Alamitos, California • Englewood, Colorado + 10 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 21
States / cities: Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 15 more

Conditions: Schizophrenia, Cognition
Interventions: Sertindole, Quetiapine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 26
States / cities: Garden Grove, California • National City, California • Pasadena, California + 23 more

Conditions: Lung Diseases, Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: Up to 100 Years
Enrollment: 3,459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more

Conditions: Prostate Cancer
Interventions: PSMA ADC; Drug
Lead sponsor: Progenics Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Tucson, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more

Conditions: Anaemia
Interventions: Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 161
States / cities: Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more

Conditions: Generalized Anxiety Disorder
Interventions: pexacerfont, escitalopram, placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 51
States / cities: Mesa, Arizona • Burbank, California • Costa Mesa, California + 42 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: HU6, Placebo; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Beverly Hills, California • Torrance, California • Hialeah, Florida + 11 more

Conditions: Obesity
Interventions: Behavioral counseling and optional meal replacement program; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Macular Degeneration
Interventions: Low-Intensity Laser Treatment; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 24
States / cities: Mesa, Arizona • Peoria, Arizona • San Francisco, California + 20 more

Conditions: COVID-19 Pneumonia
Interventions: Tociliuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 24
States / cities: Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more

Conditions: Post SARS-CoV2 (COVID-19)
Interventions: Tele-exercise; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions: Ixabepilone, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 72
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 54 more

Conditions: Advanced Angiosarcoma
Interventions: TRC105, Votrient; Biological · Drug
Lead sponsor: Tracon Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 26
States / cities: Tucson, Arizona • Palo Alto, California • Santa Monica, California + 22 more

Conditions: Osteosarcoma
Interventions: Saracatinib, Placebo; Drug
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: 15 Years to 74 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 13 more

Conditions: Bacterial Infections, Diabetic Foot, Osteomyelitis
Interventions: Tigecycline, Ertapenem; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 26
States / cities: Los Angeles, California • Northridge, California • San Francisco, California + 20 more

Conditions: Healthy Volunteer, Opioid-use Disorder
Interventions: INDV-2000, Placebo, SUBOXONE® sublingual film; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas

Search by objective public record fields.

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Survivorship Promotion In Reducing IGF-1 Trial

Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome

Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment

Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit

Pelvic Floor Disorder Assessment of Knowledge and Symptoms: an Educational Model in Spanish-Speaking Women

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies

Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia

Genetic Modifiers of Cystic Fibrosis: Sibling Study

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

Johns Hopkins Weight Management Center Patient Data

Complications of Age-Related Macular Degeneration Prevention Trial

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

Home-Based Exercise Tele-Rehabilitation After COVID-19

Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder